Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 3
2003 2
2004 8
2005 2
2008 3
2010 1
2011 4
2012 1
2013 2
2014 2
2015 2
2016 4
2017 10
2018 7
2019 9
2020 17
2021 17
2022 14
2023 9
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Results by year

Filters applied: . Clear all
Page 1
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M; EMPEROR-Preserved Trial Investigators. Anker SD, et al. N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27. N Engl J Med. 2021. PMID: 34449189 Clinical Trial.
LDL cholesterol and atherosclerosis: The evidence.
Guijarro C, Cosín-Sales J. Guijarro C, et al. Among authors: cosin sales j. Clin Investig Arterioscler. 2021 May;33 Suppl 1:25-32. doi: 10.1016/j.arteri.2020.12.004. Clin Investig Arterioscler. 2021. PMID: 33966809 Free article. English, Spanish.
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators. Schwartz GG, et al. N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7. N Engl J Med. 2018. PMID: 30403574 Free article. Clinical Trial.
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Hagström E, Steg PG, Szarek M, Bhatt DL, Bittner VA, Danchin N, Diaz R, Goodman SG, Harrington RA, Jukema JW, Liberopoulos E, Marx N, McGinniss J, Manvelian G, Pordy R, Scemama M, White HD, Zeiher AM, Schwartz GG; ODYSSEY OUTCOMES Investigators. Hagström E, et al. Circulation. 2022 Aug 30;146(9):657-672. doi: 10.1161/CIRCULATIONAHA.121.057807. Epub 2022 Jun 30. Circulation. 2022. PMID: 35770629 Free PMC article. Clinical Trial.
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.
Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Ray KK, et al. Lancet Diabetes Endocrinol. 2019 Aug;7(8):618-628. doi: 10.1016/S2213-8587(19)30158-5. Epub 2019 Jul 1. Lancet Diabetes Endocrinol. 2019. PMID: 31272931 Free article. Clinical Trial.
Comments on the 2019 ESC/EAS guidelines for the management of dyslipidemias.
SEC Working Group for the 2019 ESC EAS guidelines for the management of dyslipidaemias, Expert Reviewers for the 2019 ESC guidelines for the management of dyslipidaemias, SEC Guidelines Committe; Grupo de Trabajo de la SEC para la guía ESC 2019 sobre el tratamiento de las dislipemias; Revisores expertos para la ESC 2019 sobre el tratamiento de las dislipemias; Comité de Guías de la SEC. SEC Working Group for the 2019 ESC EAS guidelines for the management of dyslipidaemias, Expert Reviewers for the 2019 ESC guidelines for the management of dyslipidaemias, SEC Guidelines Committe, et al. Rev Esp Cardiol (Engl Ed). 2020 May;73(5):348-353. doi: 10.1016/j.rec.2019.11.019. Epub 2020 Mar 21. Rev Esp Cardiol (Engl Ed). 2020. PMID: 32205101 English, Spanish. No abstract available.
Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish Immunotherapy Registry of Cardiovascular Toxicity.
Zatarain-Nicolás E, Martín P, Márquez Rodas I, Virizuela J, Martín García A, Mitroi C, Cosín Sales J, Barrios V, Sánchez-Cabo F, Ibañez B, de Castro Carpeño J, López Fernández T. Zatarain-Nicolás E, et al. Among authors: cosin sales j. Clin Transl Oncol. 2023 Nov;25(11):3073-3085. doi: 10.1007/s12094-023-03217-2. Epub 2023 May 25. Clin Transl Oncol. 2023. PMID: 37227656 Review.
Comments on the 2016 ESC Guidelines for the Management of Atrial Fibrillation.
Arribas F; SEC Working Group for the 2016 ESC Guidelines for the Management of Atrial Fibrillation:; Arribas F, Roldán I, Luis Merino J, Roldán V, Arenal Ÿ, Tamargo J, Ruiz-Granell R, Mont L, Anguita M, Marín F; Reviewers for the 2016 ESC Guidelines for the Management of Atrial Fibrillation:; Barrios Alonso V, Barón G, Esquivias, Cosín Sales J, Díaz Infante E, Escobar Cervantes C, Ferreiro Gutiérrez JL, Guerra Ramos JM, Jiménez Candil FJ, Pérez Castellano N, Sambola Ayala A, Tello Montoliu A; SEC Guidelines Committee:; San Román A, Alfonso F, Arribas F, Evangelista A, Ferreira I, Jiménez M, Marín F, de Isla LP, Rodríguez Padial L, Sánchez PL, Sionis A, Vázquez R. Arribas F, et al. Among authors: cosin sales j. Rev Esp Cardiol (Engl Ed). 2017 Jan;70(1):2-8. doi: 10.1016/j.rec.2016.11.032. Rev Esp Cardiol (Engl Ed). 2017. PMID: 28038728 English, Spanish. No abstract available.
Comments on the 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension.
SEC Working Group for the 2018 ESC ESH Guidelines on Arterial Hypertension; Expert Reviewers for the 2018 ESC ESH Guidelines on Arterial Hypertension; SEC Guidelines Committee. SEC Working Group for the 2018 ESC ESH Guidelines on Arterial Hypertension, et al. Rev Esp Cardiol (Engl Ed). 2019 Feb;72(2):104-108. doi: 10.1016/j.rec.2018.12.001. Rev Esp Cardiol (Engl Ed). 2019. PMID: 30704721 English, Spanish. No abstract available.
Comments on the 2018 ESC/EACTS Guidelines for Myocardial Revascularization.
SEC Working Group for the 2018 ESC/EACTS Guidelines for Myocardial Revascularization; Expert Reviewers for the 2018 ESC/EACTS Guidelines for Myocardial Revascularization; SEC Guidelines Committee. SEC Working Group for the 2018 ESC/EACTS Guidelines for Myocardial Revascularization, et al. Rev Esp Cardiol (Engl Ed). 2019 Jan;72(1):16-20. doi: 10.1016/j.rec.2018.11.010. Rev Esp Cardiol (Engl Ed). 2019. PMID: 30580785 Review. English, Spanish. No abstract available.
103 results